{"entity":{"id":"nct03774056","kind":"trial","name":"A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.","aka":[],"tldr":"A phase 1 trial of Deutenzalutamide run by Hinova Pharmaceuticals Inc., completed.","summary":"A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients. is a phase 1 interventional study registered as NCT03774056 by Hinova Pharmaceuticals Inc., with 43 participants enrolled, started 2017-02-10. Conditions recorded: Metastatic Castration Resistant Prostate Cancer. Interventions recorded: HC-1119.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT03774056","url":"https://clinicaltrials.gov/study/NCT03774056"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":["deutenzalutamide"],"companies":["hinova-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03774056","phase":"1","setting":"A Phase I Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients With Metastatic Castration-Resistant Prostate Cancer.","sponsor":"Hinova Pharmaceuticals Inc.","enrolled":43,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03774056/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"}],"drug":[{"id":"deutenzalutamide","kind":"drug","name":"Deutenzalutamide","route":"/drugs/deutenzalutamide/"}],"company":[{"id":"hinova-pharmaceuticals","kind":"company","name":"Hinova Pharmaceuticals","route":"/companies/hinova-pharmaceuticals/"}]}}